Biotech Firms CBT and Maymufa Report Good News(2011/8)

August 31st, 2011 | Categories: 2011 | Tags:

Taipei, Aug. 31, 2011 (CENS)–Two Taiwanese biotech companies, Chunghwa Biomedical Technology Co., Ltd. (CBT) and Maymufa Company, Ltd., reported good news recently.

CBT said that the European Medicines Agency (EMA) has completed its administrative validation for Ridaforolimus, an oral anti-cancer drug developed for metastatic soft-tissue or bone sarcomas in patients who respond favorably to chemotherapy. CBT supplies the API (Active Pharmaceutical Ingredients) of Ridaforolimus, which was developed by international pharmaceutical company Merck.

The analysts pointed out that the market for the new drug is expected to reach US$350 million by 2015, and CBT will expand shipments of the new drug to Merck in 2012, with CBT to ship 20 to 50 kgs of the APIs to Merck by this year-end.

CBT said that Merck also applied with the Food and Drug Administration (FDA) for Ridaforolimus validation, with the certification expected to be fast-tracked due to the new drug having proven very effective in clinical tests. The FDA validation should take two months and be completed by the end of this year, CBT said.

To meet strong demand in China, Maymufa`s new shampoo factory in Taiwan recently became GMP/ISO 22716 certified to make cosmetics, with the new factory to multiply capacity by 10-fold to generate more business opportunities in China.

(by Quincy Liang)


Referrer Plugin made by Electric Guitars.